519032-06-5

• 常用中文名：5,6-二羟基-2-对甲苯基基嘧啶-4-甲酸甲酯
• 常用英文名：5,6-Dihydroxy-2-p-tolyl-pyrimidine-4-carboxylic acid methyl ester
• CAS号：519032-06-5
• 分子式：C₁₃H₁₂N₂O₄
• 分子量：260.24500
• 发布时间：2018-12-24 20:18:05
• 更新时间：2024-02-04 11:14:22

名称

• 中文名: 5,6-二羟基-2-对甲苯-嘧啶-4-羧酸甲酯
• 英文名: 5,6-dihydroxy-2-p-tolyl-pyrimidine-4-carboxylic acid methyl ester
• 英文别名: MFCD04974513

物化性质

• 沸点: 401.9±55.0 °C at 760 mmHg
• 分子式: C₁₃H₁₂N₂O₄
• 分子量: 260.24500
• 精确质量: 260.08000
• PSA: 92.54000
• LogP: 1.64980
• 外观性状: 棕色固体
• 储存条件: 2-8°C，干燥，密封

安全

• 危害码 (欧洲): Xn
• 海关编码: 2933599090

合成路线

104-85-8 ~% 519032-06-5

文献：Pace, Paola; Di Francesco, M. Emilia; Gardelli, Cristina; Harper, Steven; Muraglia, Ester; Nizi, Emanuela; Orvieto, Federica; Petrocchi, Alessia; Poma, Marco; Rowley, Michael; Scarpelli, Rita; Laufer, Ralph; Paz, Odalys Gonzalez; Monteagudo, Edith; Bonelli, Fabio; Hazuda, Daria; Stillmock, Kara A.; Summa, Vincenzo Journal of Medicinal Chemistry, 2007 , vol. 50, # 9 p. 2225 - 2239

33262-65-6 ~% 519032-06-5

文献：Pace, Paola; Di Francesco, M. Emilia; Gardelli, Cristina; Harper, Steven; Muraglia, Ester; Nizi, Emanuela; Orvieto, Federica; Petrocchi, Alessia; Poma, Marco; Rowley, Michael; Scarpelli, Rita; Laufer, Ralph; Paz, Odalys Gonzalez; Monteagudo, Edith; Bonelli, Fabio; Hazuda, Daria; Stillmock, Kara A.; Summa, Vincenzo Journal of Medicinal Chemistry, 2007 , vol. 50, # 9 p. 2225 - 2239

19227-13-5 ~% 519032-06-5

文献：Pace, Paola; Di Francesco, M. Emilia; Gardelli, Cristina; Harper, Steven; Muraglia, Ester; Nizi, Emanuela; Orvieto, Federica; Petrocchi, Alessia; Poma, Marco; Rowley, Michael; Scarpelli, Rita; Laufer, Ralph; Paz, Odalys Gonzalez; Monteagudo, Edith; Bonelli, Fabio; Hazuda, Daria; Stillmock, Kara A.; Summa, Vincenzo Journal of Medicinal Chemistry, 2007 , vol. 50, # 9 p. 2225 - 2239

上下游产品

上游产品  3
104-85-8 33262-65-6 19227-13-5
下游产品  0

海关

海关编码	2933599090
中文概述	2933599090. 其他结构上有嘧啶环的化合物(包括其他结构上有哌嗪环的化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%
申报要素	品名, 成分含量, 用途, 乌洛托品请注明外观, 6－己内酰胺请注明外观, 签约日期
Summary	2933599090. other compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%